Flexion Therapeutics is a biopharmaceutical company focused on advancing innovative, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.
Total raised: $53M
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| - | 5AM Ventur... | 5amventure... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.12.2012 | Series B | $20M | - |
| 16.10.2009 | Series A | $33M | - |
Mentions in press and media 11
| Date | Title | Description |
| 02.02.2026 | 3 Ways Health Brands Can Design Digital Experiences That Users Won’t Abandon | According to new research, nearly half of users ultimately abandon the digital health or wellness technologies they adopt. This startling finding reveals a major challenge amid the industry’s rapid growth. Health and wellness technologies a... |
| 11.10.2021 | Sure, dogs are cute. But there’s another dimension to the battle over Zooplus | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Even before the pandemic unleashed a boom in puppy adoptions, the fortunes of the pet-care indust... |
| 06.09.2021 | Flexion Therapeutics : to Present at the Wells Fargo 2021 Virtual Healthcare Conference | BURLINGTON, Mass. - Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference... |
| 04.08.2021 | Flexion Therapeutics : Reports Second-Quarter 2021 Financial Results and Recent Business Highlights | ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarter Net loss in Q2 2021 decreased by $10.4 million (32%), as compared to Q2 2... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 04.12.2012 | Flexion Therapeutics Inks $20M in Series B | WOBURN, MA, Flexion Therapeutics announced that the company has secured $20 million in a Series B financing round led by new investor, Novo Ventures. >> Click here for more funding data on Flexion Therapeutics >> To export F... |
| 04.12.2012 | Flexion Therapeutics Raises $20M in Series B Financing | Flexion Therapeutics, a Woburn, MA-based company that discovers and develops innovative therapeutics for musculoskeletal disorders, has raised $20m in Series B financing. The round led by new investor Novo Ventures, with participation from ... |
| 04.12.2012 | FLEXION THERAPEUTICS SECURES $20 MILLION IN SERIES B FINANCING | - |
| 29.01.2010 | Flexion Therapeutics Closes $42M Series A Funding and Three in-licensing Deals | Flexion Therapeutics, aWoburn, MA-based developer of drug candidates through clinically meaningful proof of concept and beyond, has received an equity financing from Pfizer Venture Investments which allowed the company to close its $42m Ser... |
| 16.10.2009 | FLEXION THERAPEUTICS RAISES $33 MILLION IN SERIES A FINANCING | - |
Show more